Bank of New York Mellon
BTAI icon

Bank of New York Mellon’s BioXcel Therapeutics BTAI Stock Holding History

Bank of New York Mellon’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-7,692
Closed -$347K – 4142
2024
Q1 		$347K Sell
7,692
-215
-3% -$10.3K ﹤0.01% 3714
2023
Q4 		$373K Sell
7,907
-94
-1% -$5.23K ﹤0.01% 3707
2023
Q3 		$324K Buy
8,001
+931
+13% +$94.1K ﹤0.01% 3772
2023
Q2 		$753K Buy
7,070
+2,249
+47% +$749K ﹤0.01% 3373
2023
Q1 		$1.44M Buy
4,821
+324
+7% +$138K ﹤0.01% 2973
2022
Q4 		$1.55M Buy
4,497
+421
+10% +$102K ﹤0.01% 2985
2022
Q3 		$771K Buy
4,076
+275
+7% +$63.8K ﹤0.01% 3330
2022
Q2 		$802K Buy
3,801
+152
+4% +$32K ﹤0.01% 3317
2022
Q1 		$1.22M Buy
3,649
+102
+3% +$29.6K ﹤0.01% 3193
2021
Q4 		$1.15M Buy
3,547
+161
+5% +$69.1K ﹤0.01% 3300
2021
Q3 		$1.65M Buy
3,386
+282
+9% +$124K ﹤0.01% 3108
2021
Q2 		$1.44M Sell
3,104
-676
-18% -$368K ﹤0.01% 3204
2021
Q1 		$2.61M Sell
3,780
-84
-2% -$67.6K ﹤0.01% 2770
2020
Q4 		$2.86M Buy
3,864
+389
+11% +$303K ﹤0.01% 2637
2020
Q3 		$2.41M Buy
3,475
+197
+6% +$148K ﹤0.01% 2558
2020
Q2 		$2.78M Buy
3,278
+162
+5% +$106K ﹤0.01% 2493
2020
Q1 		$1.11M Buy
3,116
+1,902
+157% +$684K ﹤0.01% 2896
2019
Q4 		$284K Hold
1,214
– – ﹤0.01% 3824
2019
Q3 		$137K Buy
1,214
+84
+7% +$13.2K ﹤0.01% 3976
2019
Q2 		$198K Buy
+1,130
New +$191K ﹤0.01% 3929

Other funds holding BTAI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of New York Mellon's BTAI Position: Q2 2024 in Review

Bank of New York Mellon sold out of BioXcel Therapeutics (BTAI) in Q2 2024, closing a stake of 7,692 shares — an estimated $347K sold.

Bank of New York Mellon first reported a position in BTAI in Q2 2019 and held it in 20 quarters. The position peaked at $2.86M in Q4 2020. 74 funds tracked by Wall St. Rank hold BTAI as of Q2 2024.

  • Bank of New York Mellon reported no remaining BioXcel Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Bank of New York Mellon sold 7,692 BioXcel Therapeutics shares in Q2 2024, an estimated $347K.
  • Bank of New York Mellon first reported a position in BioXcel Therapeutics in Q2 2019 and held it in 20 quarters.
  • Bank of New York Mellon's BioXcel Therapeutics position peaked at $2.86M in Q4 2020.
  • 74 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2024.

Based on Bank of New York Mellon's 13F filing for Q2 2024, filed 25 Jul 2024.